Evidence map›Paper›PMID 35127499›Full record

ArticleFrontiers in oncology2021

MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI.

Tong Chen, Zhiyuan Zhang, Shuangxiu Tan, Yueyue Zhang, Chaogang Wei, Shan Wang, Wenlu Zhao, Xusheng Qian, Zhiyong Zhou, Junkang Shen and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tong ChenDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Zhiyuan ZhangSchool of Medical Imaging, Biomedical Engineering, Xuzhou Medical University, Xuzhou, China.
Shuangxiu TanDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Yueyue ZhangDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Chaogang WeiDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Shan WangDepartment of Radiology, Jiangsu Jiangyin People's Hospital, Jiangyin, China.
Wenlu ZhaoDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Xusheng QianSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China.
Zhiyong ZhouSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China.
Junkang ShenDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Yakang DaiSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China.
Jisu HuSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the performance of radiomics to that of the Prostate Imaging Reporting and Data System (PI-RADS) v2.1 scoring system in the detection of clinically significant prostate cancer (csPCa) based on biparametric magnetic resonance imaging (bpMRI) vs. multiparametric MRI (mpMRI).

methodsA total of 204 patients with pathological results were enrolled between January 2018 and December 2019, with 142 patients in the training cohort and 62 patients in the testing cohort. The radiomics model was compared with the PI-RADS v2.1 for the diagnosis of csPCa based on bpMRI and mpMRI by using receiver operating characteristic (ROC) curve analysis.

resultsThe radiomics model based on bpMRI and mpMRI signatures showed high predictive efficiency but with no significant differences (AUC = 0.975 vs 0.981, p=0.687 in the training cohort, and 0.953 vs 0.968, p=0.287 in the testing cohort, respectively). In addition, the radiomics model outperformed the PI-RADS v2.1 in the diagnosis of csPCa regardless of whether bpMRI (AUC = 0.975 vs. 0.871, p= 0.030 for the training cohort and AUC = 0.953 vs. 0.853, P = 0.024 for the testing cohort) or mpMRI (AUC = 0.981 vs. 0.880, p= 0.030 for the training cohort and AUC = 0.968 vs. 0.863, P = 0.016 for the testing cohort) was incorporated.

conclusionsOur study suggests the performance of bpMRI- and mpMRI-based radiomics models show no significant difference, which indicates that omitting DCE imaging in radiomics can simplify the process of analysis. Adding radiomics to PI-RADS v2.1 may improve the performance to predict csPCa.

Indexed as

biparametric MRImultiparametric MRIPI-RADS v2.1prostate cancerradiomics

Identifiers

PMID35127499
PMCPMC8810653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.